Merrimack Pharmaceuticals reports fourth quarter 2014 financial results
Merrimack Pharmaceuticals reported the net loss for 2014 was $83.6 million compared with net loss for 2013 of $130.7 million. Merrimack expects to be able to fund operations into 2016 through its unrestricted cash and equivalents of $124.0 million as of December 31, 2014. February 26, 2015